Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Tau PET Radiotracers [18F]GTP1 vs [18F]PI-2620 or [18F]MK-6240 in AD
NCT04566003Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]GTP1 in Alzheimer's disease (AD) (2 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events (AEs) at 4 days, Brain tau burden as measured by [18F]PI-2620 - PET at 1 hour and 2 more. Started Oct 2020; status: completed.
02
Drugs
[18F]GTP1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04566003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566003.